RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

NCT06063018 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer Recurrent

Interventions

DRUG: RC48 + Tislelizumab

Sponsor

Peking Union Medical College Hospital